Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
Jazz Pharmaceuticals (Nasdaq: JAZZ) will report its 2025 third quarter financial results on Wednesday, November 5, 2025 after the U.S. market close. Management will host a live audio webcast at 4:30 p.m. EST / 9:30 p.m. GMT to discuss the results and provide a business and financial update.
Participants may register in advance via the Investors section of the Jazz Pharmaceuticals website and are recommended to register at least 15 minutes before the webcast. A replay will be available in the Investors events and presentations area.
Jazz Pharmaceuticals is a global biopharma company focused on therapies for sleep disorders, epilepsy, and oncology, headquartered in Dublin with global R&D and manufacturing operations.
Jazz Pharmaceuticals (Nasdaq: JAZZ) riporterà i risultati finanziari del terzo trimestre 2025 il mercoledì 5 novembre 2025 dopo la chiusura del mercato statunitense. Il management terrà una webcast audio in diretta alle 16:30 EST / 21:30 GMT per discutere i risultati e fornire un aggiornamento sull'andamento aziendale e finanziario.
I partecipanti possono registrarsi in anticipo tramite la sezione Investitori del sito web di Jazz Pharmaceuticals e si consiglia di registrarsi almeno 15 minuti prima della trasmissione. Una replica sarà disponibile nell'area Investitori eventi e presentazioni.
Jazz Pharmaceuticals è una società biofarmaceutica globale focalizzata su terapie per disturbi del sonno, epilessia e oncologia, con sede a Dublino e operazioni globali di ricerca e sviluppo e produzione.
Jazz Pharmaceuticals (Nasdaq: JAZZ) informará sus resultados financieros del tercer trimestre de 2025 el miércoles 5 de noviembre de 2025 después del cierre del mercado de Estados Unidos. La dirección organizará un webcast en vivo por audio a las 4:30 p.m. EST / 9:30 p.m. GMT para discutir los resultados y proporcionar una actualización comercial y financiera.
Los participantes pueden registrarse por adelantado a través de la sección de Inversores del sitio web de Jazz Pharmaceuticals y se recomienda registrarse al menos 15 minutos antes del webcast. Una reproducción estará disponible en el área de eventos y presentaciones de inversores.
Jazz Pharmaceuticals es una empresa biofarmacéutica global centrada en terapias para trastornos del sueño, epilepsia y oncología, con sede en Dublín y operaciones globales de I+D y fabricación.
Jazz Pharmaceuticals (나스닥: JAZZ)는 미국 시장 마감 후 2025년 3분기 재무 실적을 발표합니다. 경영진은 동부표준시 기준 오후 4:30 / GMT 오후 9:30에 생방송 음성 웹캐스트를 주최하여 결과를 논의하고 비즈니스 및 재무 업데이트를 제공합니다.
참가자는 Jazz Pharmaceuticals 웹사이트의 투자자 섹션을 통해 미리 등록할 수 있으며, 웹캐스트 시작 최소 15분 전에 등록하는 것이 좋습니다. 재방송은 투자자 이벤트 및 프레젠테이션 영역에서 이용 가능합니다.
Jazz Pharmaceuticals는 수면 장애, 간질 및 종양학 치료에 초점을 맞춘 글로벌 생명공학 제약 회사로, 더블린에 본사를 두고 글로벌 R&D 및 제조 운영을 하고 있습니다.
Jazz Pharmaceuticals (Nasdaq : JAZZ) publiera ses résultats financiers du troisième trimestre 2025 le mercredi 5 novembre 2025 après la clôture du marché américain. La direction animera un webcast audio en direct à 16 h 30 HNE / 21 h 30 HGMT pour discuter des résultats et fournir une mise à jour commerciale et financière.
Les participants peuvent s'inscrire à l'avance via la section Investisseurs du site Web de Jazz Pharmaceuticals et il leur est recommandé de s'inscrire au moins 15 minutes avant le webcast. Une rediffusion sera disponible dans la section Investisseurs événements et présentations.
Jazz Pharmaceuticals est une entreprise biopharmaceutique mondiale axée sur les thérapies pour les troubles du sommeil, l'épilepsie et l'oncologie, dont le siège est à Dublin, avec des activités mondiales de R&D et de fabrication.
Jazz Pharmaceuticals (Nasdaq: JAZZ) wird seine finanziellen Ergebnisse des dritten Quartals 2025 am Mittwoch, 5. November 2025 nach Börsenschluss in den USA bekannt geben. Das Management wird eine Live-Audio-Webcast um 16:30 Uhr EST / 21:30 Uhr GMT veranstalten, um die Ergebnisse zu diskutieren und ein geschäftliches sowie finanzielles Update zu geben.
Teilnehmer können sich im Voraus über den Bereich Anleger der Jazz Pharmaceuticals-Website registrieren und wird empfohlen, sich mindestens 15 Minuten vor dem Webcast anzumelden. Eine Wiedergabe wird im Bereich Investoren-Veranstaltungen und -Präsentationen verfügbar sein.
Jazz Pharmaceuticals ist ein globales Biopharmaunternehmen, das sich auf Therapien für Schlafstörungen, Epilepsie und Onkologie fokussiert, mit Hauptsitz in Dublin und globalen F&E- und Herstellungsaktivitäten.
Jazz Pharmaceuticals (ناسداك: JAZZ) ستعلن عن نتائجها المالية للربع الثالث من 2025 يوم الأربعاء 5 نوفمبر 2025 بعد إغلاق السوق الأمريكية. ستستضيف الإدارة بثاً صوتياً مباشراً في الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة / 9:30 مساءً بتوقيت غرينتش لمناقشة النتائج وتقديم تحديث عملي ومالي.
يمكن للمشاركين التسجيل مسبقاً عبر قسم المستثمرين في موقع Jazz Pharmaceuticals الإلكتروني، ويُوصى بالتسجيل قبل 15 دقيقة على الأقل قبل البث. ستكون إعادة العرض متاحة في منطقة فعاليات ومقدمات المستثمرين.
تُعد Jazz Pharmaceuticals شركة أدوية حيوية عالمية تركز على علاجات لاضطرابات النوم والصرع والسرطان، ومقرها دبلن وتعمل على مستوى العالم في مجالات البحث والتطوير والتصنيع.
Jazz Pharmaceuticals (纳斯达克：JAZZ) 将在美国市场收盘后公布其 2025 年第三季度财务业绩，时间为 2025 年 11 月 5 日（星期三）。管理层将于 美国东部时间下午 4:30 / 世界协调时/格林威治标准时间晚上 9:30 举行实时有声网路广播，讨论业绩并提供业务与财务更新。
参与者可通过 Jazz Pharmaceuticals 网站的投资者部分提前注册，建议在广播开始前至少注册 15 分钟。回放将于投资者活动与演示区提供。
Jazz Pharmaceuticals 是一家全球生物制药公司，专注于治疗睡眠障碍、癫痫和肿瘤学领域，总部位于都柏林，拥有全球研发和制造业务。
- None.
- None.
Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts:
Investors:
Jack Spinks
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-third-quarter-financial-results-on-november-5-2025-302590829.html
SOURCE Jazz Pharmaceuticals plc
FAQ
When will Jazz Pharmaceuticals (JAZZ) report Q3 2025 results?
What time is the Jazz (JAZZ) Q3 2025 earnings webcast?
How can investors register for the Jazz Pharmaceuticals (JAZZ) November 5, 2025 webcast?
Will a replay of the Jazz Pharmaceuticals (JAZZ) Q3 2025 webcast be available?
What topics will Jazz Pharmaceuticals (JAZZ) cover in the November 5, 2025 update?
